Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11426385

    Methods of improving cancer chemotherapy

    THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11421284

    Methods for predicting drug responsiveness in cancer patients

    Allarity Therapeutics Europe ApS · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11421034

    Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

    Five Prime Therapeutics, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11421010

    T cells expressing membrane-anchored IL-12 for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11419898

    Combinatorial cancer immunotherapy

    Senti Biosciences, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11419934

    Use of VDAS to enhance immunomodulating therapies against tumors

    Oncotelic Therapeutics, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11419844

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11414488

    Methods for treating cancer

    BicycleRD Limited · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11413329

    Cancer cell trap

    The Board of Regents of the University of Texas System · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11414458

    Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies

    The Board of Regents of the University of Oklahoma · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11406697

    Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus

    Regents of the University of Minnesota · Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11406643

    Targeting kinases for the treatment of cancer metastasis

    The Board of Regents of the University of Texas System · Granted Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11401507

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11401506

    Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

    Board nf Regents The Inivercitvof Texas Cvctom · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11401341

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11401503

    Methods of growing tumor infiltrating lymphocytes in gas-permeable containers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11400116

    Systems and methods for targeting cancer cells

    The Regents of the University of California · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11396647

    Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Jul 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11389497

    Pharmaceutical composition for treating cancer

    Prime Bio, Inc. · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11389432

    Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent

    Corcept Therapeutics Incorporated · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11389480

    Human monoclonal antibody targeting TNFR2 for cancer immunotherapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11389544

    Formation of functionalized cancer targeting nanoparticles by supramolecular co-assembly

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11384337

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11376247

    Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11377491

    Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11377451

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11376313

    Cancer treatment

    Propanc Pty Ltd · Granted Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11369697

    Liposome nanoparticles for tumor magnetic resonance imaging

    United Kingdom Research and Innovation · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11369637

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11365250

    Compositions and methods for cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11364235

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11364266

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11357742

    Methods for treating cancer

    X4 Pharmaceuticals, Inc. · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11357795

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11357842

    PD-L1 targeting DNA vaccine for cancer immunotherapy

    Vaximm AG · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11357841

    Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11351198

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11352395

    Anticancer peptides

    IDP DISCOVERY PHARMA, S.L. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11351199

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11351185

    Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11351197

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11344580

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11345733

    Colon and pancreas cancer specific antigens and antibodies

    PRECISION BIOLOGICS, INC. · Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11344581

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11344579

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11339213

    Methods and compositions for treatment of cancer

    MEREO BIOPHARMA 5, INC. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11338028

    Cancer vaccines targeting LEMD1 and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11338026

    Identification of immunologically protective neo-epitopes for the treatment of cancers

    UNIVERSITY OF CONNECTICUT · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.